Cargando…

Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease

BACKGROUND: Scleroderma (SSc) patients with active interstitial lung disease (ILD) experience a decline in lung function and increased mortality; cyclophosphamide (CYC) therapy may stabilize lung function at one and two years follow-up. Long-term lung function and survival outcomes of SSc patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mittoo, S, Wigley, Fredrick M, Wise, Robert A, Woods, Adrianne, Xiao, Huiqing, Hummers, Laura K
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Open 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087310/ https://www.ncbi.nlm.nih.gov/pubmed/21552414 http://dx.doi.org/10.2174/1874312901105010001

Ejemplares similares

Race and Association With Disease Manifestations and Mortality in Scleroderma: A 20-Year Experience at the Johns Hopkins Scleroderma Center and Review of the Literature
por: Gelber, Allan C., et al.
Publicado: (2013)

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
por: Tashkin, Donald P, et al.
Publicado: (2016)

Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma
por: Fava, Andrea, et al.
Publicado: (2016)

Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study
por: McMahan, Zsuzsanna, et al.
Publicado: (2015)

Scleroderma-related interstitial lung disease
por: Suliman, Sally, et al.
Publicado: (2017)

Paclitaxel Modulates TGFβ Signaling in Scleroderma Skin Grafts in Immunodeficient Mice
por: Liu, Xialin, et al.
Publicado: (2005)

Abnormal gene expression in CD8 T cells from the lungs of scleroderma patients
por: Luzina, IG, et al.
Publicado: (2002)

Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010)

Scleroderma and interstitial lung disease - A case report
por: Gul, Fahad, et al.
Publicado: (2022)

Type 2 cytokines and scleroderma interstitial lung disease
por: Pellicano, Chiara, et al.
Publicado: (2023)

Global analysis of gene expression in unseparated and CD8+ cells from bronchoalveolar lavage of patients with scleroderma lung disease
por: Luzina, IG, et al.
Publicado: (2001)

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis
por: Shenoy, Padmanabha D., et al.
Publicado: (2016)

Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States
por: Bernstein, Elana J., et al.
Publicado: (2022)

Defining genetic risk factors for scleroderma-associated interstitial lung disease: IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
por: Stock, Carmel J. W., et al.
Publicado: (2020)

Safety and Tolerability of Thrombin Inhibition in Scleroderma‐Associated Interstitial Lung Disease
por: Silver, R. M., et al.
Publicado: (2019)

Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis
por: Casciola-Rosen, Livia, et al.
Publicado: (1997)

Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange
por: Nagamura, Norihiro, et al.
Publicado: (2016)

Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
por: Yamakawa, Hideaki, et al.
Publicado: (2018)

Intravenous Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease: A Long Term Study
por: Simeón-Aznar, C.P, et al.
Publicado: (2008)

Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease
por: Fidler, Lee M., et al.
Publicado: (2021)

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
por: Nannini, Carlotta, et al.
Publicado: (2008)

Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality
por: Volkmann, Elizabeth R., et al.
Publicado: (2022)

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases
por: Nucera, Valeria, et al.
Publicado: (2021)

Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
por: Baqir, Misbah, et al.
Publicado: (2017)

Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease
por: Woo, Samuel, et al.
Publicado: (2023)

Correction: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
por: Nannini, Carlotta, et al.
Publicado: (2009)

Anti-Ro52 Antibodies and Interstitial Lung Disease in Connective Tissue Diseases Excluding Scleroderma
por: Ferreira, João Pedro, et al.
Publicado: (2012)

Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature
por: Innabi, Ayoub, et al.
Publicado: (2021)

Long-term macrolides in diffuse interstitial lung diseases
por: Faverio, Paola, et al.
Publicado: (2017)

Scleroderma specific autoantibodies in rheumatoid arthritis and Sjögren's syndrome patients with interstitial lung disease: Prevalence and associations
por: Koulouri, Vasiliki, et al.
Publicado: (2022)

EP04 Is this scleroderma lung or COVID-19 lung?
por: Malik, Dr Saadia, et al.
Publicado: (2020)

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
por: Khanna, Dinesh, et al.
Publicado: (2015)

β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up
por: De Santis, Maria, et al.
Publicado: (2011)

Interstitial Lung Disease Secondary to Long-Term Nitrofurantoin Use
por: Chin, Andrew J., et al.
Publicado: (2020)

Integrin Modulating Therapies Prevent Fibrosis and Autoimmunity in Genetic Mouse Models of Scleroderma
por: Gerber, Elizabeth E., et al.
Publicado: (2013)

Effects of cyclophosphamide combined with prednisone on TNF-α expression in treatment of patients with interstitial lung disease
por: Li, Jun, et al.
Publicado: (2019)

Can home rehabilitation impact impulse oscillometry and lung ultrasound findings in patients with scleroderma-associated interstitial lung disease? A pilot study
por: de Alegria, Samantha Gomes, et al.
Publicado: (2022)

Evaluation and management approaches for scleroderma lung disease
por: Schoenfeld, Sara R., et al.
Publicado: (2017)

Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide
por: Tourkina, Elena, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pp7p3tsiq7hno9qpt7ma5qqgte